ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 238.28 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 177.79K shares, a 49.95% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 60.49K shares, a 61.45% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 22.24K shares, a 85.53% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 534.35K shares, a 90.08% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 5.38M shares, a 679.11% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 691.16K shares, a 242.99% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 201.51K shares, a 30.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 177.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 238.28K shares 10-Q · filed 2026-08-05 | 238.28K shares derived: sum of 3 quarters · filed 2026-08-05 | 260.52K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 60.49K shares 10-Q · filed 2026-05-06 | 60.49K shares derived: sum of 2 quarters · filed 2026-05-06 | 82.73K shares derived: sum of 3 quarters · filed 2026-05-06 | 437.94K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 22.24K shares derived: sum of 2 quarters · filed 2026-02-25 | 377.45K shares derived: sum of 3 quarters · filed 2026-02-25 | 534.35K shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 22.24K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 377.45K shares derived: sum of 2 quarters · filed 2025-10-28 | 534.35K shares 10-Q · filed 2025-10-28 | 572.74K shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 355.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 512.11K shares 10-Q · filed 2025-08-06 | 550.50K shares derived: sum of 3 quarters · filed 2025-08-06 | 704.24K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 156.90K shares 10-Q · filed 2025-05-06 | 195.29K shares derived: sum of 2 quarters · filed 2025-05-06 | 349.03K shares derived: sum of 3 quarters · filed 2025-05-06 | 384.62K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 38.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 192.13K shares derived: sum of 2 quarters · filed 2025-02-25 | 227.73K shares derived: sum of 3 quarters · filed 2025-02-25 | 5.38M shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 153.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 189.33K shares derived: sum of 2 quarters · filed 2024-11-06 | 5.35M shares 10-Q · filed 2024-11-06 | 5.56M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 35.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 5.19M shares 10-Q · filed 2024-08-14 | 5.40M shares derived: sum of 3 quarters · filed 2024-08-14 | 5.62M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 5.16M shares 10-Q · filed 2024-05-14 | 5.37M shares derived: sum of 2 quarters · filed 2024-05-14 | 5.59M shares derived: sum of 3 quarters · filed 2024-05-14 | 5.74M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 211.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 431.15K shares derived: sum of 2 quarters · filed 2024-02-27 | 583.15K shares derived: sum of 3 quarters · filed 2024-02-27 | 691.16K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 219.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 371.28K shares derived: sum of 2 quarters · filed 2023-11-03 | 479.29K shares 10-Q · filed 2023-11-03 | 565.01K shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 152.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 260.01K shares 10-Q · filed 2023-08-08 | 345.73K shares derived: sum of 3 quarters · filed 2023-08-08 | 365.41K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 108.01K shares 10-Q · filed 2023-05-09 | 193.73K shares derived: sum of 2 quarters · filed 2023-05-09 | 213.41K shares derived: sum of 3 quarters · filed 2023-05-09 | 280.72K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 85.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 105.40K shares derived: sum of 2 quarters · filed 2023-02-28 | 172.71K shares derived: sum of 3 quarters · filed 2023-02-28 | 201.51K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 19.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 86.99K shares derived: sum of 2 quarters · filed 2022-11-08 | 115.79K shares 10-Q · filed 2022-11-08 | 205.23K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 67.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 96.11K shares 10-Q · filed 2022-08-04 | 185.55K shares derived: sum of 3 quarters · filed 2022-08-04 | 229.67K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 28.80K shares 10-Q · filed 2022-05-05 | 118.24K shares derived: sum of 2 quarters · filed 2022-05-05 | 162.36K shares derived: sum of 3 quarters · filed 2022-05-05 | 289.93K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 89.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | 133.56K shares derived: sum of 2 quarters · filed 2022-02-22 | 261.13K shares derived: sum of 3 quarters · filed 2022-02-22 | 288.86K shares 10-K · filed 2022-02-22 |
| 2021-09-30 | 44.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 171.69K shares derived: sum of 2 quarters · filed 2021-11-04 | 199.42K shares 10-Q · filed 2021-11-04 | 207.54K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 127.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 155.30K shares 10-Q · filed 2021-08-05 | 163.42K shares derived: sum of 3 quarters · filed 2021-08-05 | |
| 2021-03-31 | 27.73K shares 10-Q · filed 2021-05-06 | 35.85K shares derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2020-12-31 | 8.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 32.12K shares 10-K · filed 2021-02-16 | ||
| 2020-09-30 | 24.00K shares 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | 31.86K shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |